EVENTS & PRESENTATIONS
John McDermott joined in May 2008. Mr. McDermott has over 20 years of executive management, sales, marketing, and finance experience in the vascular device industry. From 2002 to 2007 he served as President of Bard Peripheral Vascular, a division of C.R. Bard, Inc. Mr. McDermott previously served as President of Global Sales for C.R. Bard's vascular surgery and endovascular businesses with responsibilities for managing a worldwide direct sales force with more than 200 representatives. Prior to that, he served for four years as President of C.R. Bard's division IMPRA, Inc., where he was responsible for global operations, including sales, marketing, research and development, manufacturing, and finance. From 1990 to 1996, Mr. McDermott served as Chief Financial Officer and later Vice President and Chief Operating Officer of IMPRA, Inc., prior to its acquisition by C.R. Bard. He is an active leader within the vascular community and is currently on the board of directors of the International Society of Endovascular Specialists.
Robert Mitchell joined in December 2010. Prior to joining us, Mr. Mitchell served as President and Chief Executive Officer of Nellix, Inc. from February 2008 until our acquisition of Nellix in December 2010. From November 2006 to February 2008, Mr. Mitchell served as Executive Vice President and Chief Operating Officer of AngioDynamics, Inc., a publicly-traded medical device company. From 2005 to 2006, Mr. Mitchell served as Chairman, President and Chief Executive Officer of Millimed Holdings, Inc., a privately-held medical device company based in Roskilde, Denmark. From 2004 to 2005, Mr. Mitchell served as Vice President of Worldwide Sales for Align Technology, Inc., a publicly-traded company. From 1987 to 2004, Mr. Mitchell held various positions with Cook Incorporated, a privately-held medical device company, including Vice President and Director, Global Sales and Marketing for various business units including diagnostic and interventional, endovascular, critical care. Mr. Mitchell holds a B.S. from the University of Utah and an M.B.A. from Indiana Wesleyan University.
Vaseem Mahboob joined in October 2015. Prior to joining Endologix, Mr. Mahboob served in several financial leadership positions at GE Healthcare, a worldwide leader in medical device development and distribution. His most recent role was Chief Financial Officer of their Global IT business. Prior to this position he was the Chief Financial Officer of their Eastern and African Emerging Markets where he oversaw financial operations for medical device distribution sales and service spanning 84 countries and four zones including Russia, Turkey, Middle East and Africa. Prior to this role, Mr. Mahboob was Chief Financial Officer of GE Healthcare's Global Ultrasound Business that is the most global and profitable within GE Healthcare. Mr. Mahboob also served as CFO of GE Healthcare's Global Magnetic Resonance (MRI) Business, along with several other global financial leadership positions. Mr. Mahboob received a B.A. in Engineering from Bangalore University, and a Masters of Business Administration (MBA) in Financial Markets and Institutions & Information Systems from State University of New York, Buffalo, NY. He is also a graduate of GE's highly regarded internal corporate audit staff where he was a senior audit manager.
Michael V. Chobotov, Ph.D. joined us in February 2016 in conjunction with the merger of TriVascular. He co-founded TriVascular as President and CEO in 1998, while creating the foundation for polymer endograft technology. He led the company’s spin-off from Boston Scientific Corporation in 2008, and continued to serve as President/CEO and member of the board of directors until 2012. Prior to co-founding TriVascular in 1998, Dr. Chobotov co-founded TransMotive Technologies, an engineering and product development consulting company. Previously, Dr. Chobotov served as Senior Vice President of R&D and board member of U.S. Electricar, and Senior Systems Engineer at Hughes Space and Communications. He also led the design of the Lunar Prospector, which was subsequently implemented as the first NASA Discovery mission. Dr. Chobotov received his Ph.D. in Mechanical Engineering, his M.S. in Mechanical Engineering and his B.S. in Engineering and Applied Science, all from the California Institute of Technology.
Matthew Thompson, M.D., joined in December 2016. Most recently, Dr. Thompson served as Professor of Vascular Surgery at St. George's, University of London and St George's Vascular Institute (SGVI). He trained at Cambridge, St. Bartholomew's Hospital, the University of Leicester and Adelaide. His awards include a Hunterian Professorship, the Moynihan travelling fellowship and the gold medal for the intercollegiate examination. Dr. Thompson is also the editor of the Oxford Textbook of Vascular Surgery and the Oxford Handbook of Vascular Surgery. He was Chair of the National Specialized Commissioning Clinical Reference Group for Vascular Services and is a founder of the British Society for Endovascular Therapy. Dr. Thompson is also a Council Member of the Vascular Society, Chairman of the Vascular Society Annual Scientific Meeting and elected President for 2018.
Joseph A. DeJohn joined in July 2008. He has more than 20 years of sales management experience in the medical device industry, including serving 17 years at C.R. Bard. During his tenure at C.R. Bard, he held sales management positions with increasing responsibilities, serving the last six years as Vice President of Sales of the Peripheral Vascular Division. In this position, he was responsible for managing a 200-person sales organization and played a leadership role in strategic planning, budgeting, recruitment, professional development, national accounts, and customer service. Prior to that, Mr. DeJohn was Director of Sales of C.R. Bard's Peripheral Technologies Division. Before joining C.R. Bard, Mr. DeJohn served five years with Bausch & Lomb Corporation in various sales management positions. Mr. DeJohn holds a B.S. in Education from Bowling Green State University.
Amanda DePalma joined in September 2014 as Vice President, Global Marketing. Her responsibilities include Global Marketing, strategic planning and brand management. Ms. DePalma has more than 19 years of medical device marketing and sales experience. Prior to joining us, Ms. DePalma held the position of Senior Director, Global Strategic Marketing at Edwards Lifesciences where she led the global strategy, business development and branding efforts for the Critical Care business unit. From 2005 to 2011 Ms. DePalma had positions of increasing responsibility at Kimberly-Clark Healthcare (now Halyard Health) including General Manager and Director of Global Strategic Marketing. Prior to that, Ms. DePalma held marketing positions at Guidant Corporation and Abbott Vascular. Ms. DePalma holds a B.S. in Marketing and an M.B.A. from the University of Florida Warrington College of Business.
Meredith Huetter joined us in February 2016 in conjunction with the merger of TriVascular. She joined TriVascular in November 2009 and has served in various roles of increasing responsibility at TriVascular, including most recently as Vice President, Clinical and Medical Affairs. Mrs. Huetter has over 15 years of medical device experience. Prior to joining TriVascular, Ms. Huetter led the EndoVascular Product Marketing organization at Medtronic, Inc., where she directed several product introductions across the aortic product line. Ms. Huetter began her career with a focus on supply chain and healthcare at Ernst & Young, a management consulting firm. She received her B.S. in Industrial Engineering from Iowa State University.
Dave Jennings joined in June 2013. Previously, Mr. Jennings spent twenty-five years as a Human Resources leader with Johnson & Johnson, twelve of those years in medical devices. At J&J, he served as Vice President, Human Resources for Advanced Sterilization Products in Irvine, CA and for nearly ten years at Neutrogena Corporation in Los Angeles. He has a proven track record of building high performance organizations in fast growing global companies. He has a diversity of health care experience, to include ophthalmology, surgical products, hospital products, instrument sterilization, pharmaceuticals and consumer products. After leaving J&J, Dave held HR Vice President roles in the Entertainment Industry as well as in a health care start-up venture in Southern California. Dave holds a Masters in Business from Claremont Graduate University.
Michael P. Maszy joined us in February 2016 in conjunction with the merger of TriVascular. He joined TriVascular in September 2010 and has served in various roles of increasing responsibility at TriVascular, including most recently as Vice President, Manufacturing. Mr. Maszy has over 15 years of medical device experience. Prior to joining TriVascular, Mr. Maszy served in various roles at Medtronic, Inc. from 2000 to 2010. Most recently, he led new product development teams at Medtronic Neurosurgery as Director of Project Management. Previously, Mr. Maszy led Operations for Medtronic Endovascular Innovations and also has held positions in manufacturing engineering in Medtronic's Peripheral Vascular and Ear, Nose & Throat divisions. Mr. Maszy received his M.B.A. in Entrepreneurial Management from The Wharton School at The University of Pennsylvania and both his M.S. and B.S. in Industrial & Systems Engineering from the University of Florida.
Laura Nagel joined us in January 2017 as Vice President, Global Quality, bringing over 25 years of medical device experience, including specific experience with catheter-based technologies in class III cardiovascular implants. Most recently, Laura served as Vice President, Quality Assurance at Direct Flow Medical, a privately-held medical device company developing and commercializing novel transcatheter heart valve products to treat structural heart disease. From 1997 to 2015, she served in several leadership positions at Edwards Lifesciences and has broad experience in quality assurance, design validation, quality engineering, microbiology, compliance and post-market surveillance. She also has extensive experience dealing with international regulatory agencies. Laura began her career at Allergan, serving in regulatory affairs, project management and product development positions from 1987 to 1997. She received a Bachelor’s degree in biological science from the University of California, Berkeley.
Shari L. O'Quinn joined us in February 2016 in conjunction with the merger of TriVascular. She joined TriVascular as Vice President, Clinical/Regulatory Affairs and Quality in September 2009. Ms. O'Quinn previously served as the Vice President of Clinical and Regulatory at Aptus Endosystems, Inc. from February 2007 to August 2009. Prior to that, Ms. O'Quinn served as Director of Clinical and Regulatory at Bard Peripheral Vascular. Ms. O'Quinn began her career as a consultant at Quintiles Medical Technology Consultants where she specialized in developing global clinical and regulatory strategies for commercialization of implantable cardiovascular devices. Ms. O'Quinn received her B.A. from the University of Virginia.
Jeff Stelk joined Endologix in August 2004. He has more than 25 years of sales and sales management experience in the medical device industry including more than 16 years in the EVAR industry with Medtronic and Endologix. Mr. Stelk is currently responsible for leading and managing the US Sales organization. Over his tenure at Endologix, Jeff has had previous roles of increasing responsibility as a Regional Sales Manager, Area Sales Manager and Director of Sales. In these roles, Jeff has delivered significant sales growth by launching multiple new products and hiring, training and developing members of the Endologix sales team. Mr. Stelk holds a BA in Business Administration from St. Ambrose University in Davenport, IA.
W. Patrick Stephens joined us in February 2016 in conjunction with the merger of TriVascular. He joined TriVascular in April 2008 and has served in various roles of increasing responsibility at TriVascular, including most recently as Vice President, Product Development. Mr. Stephens first joined TriVascular in 1999 and served as a key member of the original TriVascular team through the acquisition by Boston Scientific in 2005. Mr. Stephens has more than 20 years of experience in the design, development and manufacturing of medical devices and previously has served in roles of increasing responsibility at Medtronic, Boston Scientific and W.L. Gore. Mr. Stephens received his M.S. in Mechanical Engineering from the University of Arizona and his B.S. in Mechanical Engineering from the University of Colorado.
Board of Directors
Dan Lemaitre most recently served as the President and CEO of Direct Flow Medical. Previously, Mr. Lemaitre was the CEO of CoreValve, one of the early pioneers in transcatheter aortic valves. By 2009 revenue were at a $100 million annualized end market run rate. Dan led negotiations that resulted in the sale of CoreValve to Medtronic in a transaction valued at $800 million.
Prior to joining CoreValve, Mr. Lemaitre was a Senior Vice President at Medtronic where he headed-up strategic planning and corporate development. Dan was also a member of Medtronic’s executive and operating committees.
In 2012 Dan was part of an investor syndicate that took private a $250 million division of a major orthopedic company and served as its initial Chairman. He is also on the board of Globus Medical (NYSE: GMED) one of the fastest growing spinal companies with revenue of ~$600 million per annum. Dan serves on the Globus audit and compensation committees.
Earlier in his career Dan spent 28 years in the medical device field as an investment analyst. He began his career as a buy-side analyst in 1978 working at National City Bank in Cleveland and later, Standish Ayer & Wood in Boston. His sell-side career included 18 years with Cowen & Company, where he was a managing director and led the health care research team. In 1999, Dan moved his team to Merrill Lynch where he headed-up the medical technology effort for six years. During his Wall Street tenure, Dan was named to Institutional Investor’s All American research team for 19 consecutive years, capturing first place honors 8 times as the top-ranked medical device analyst in the country.
Dan has a BA in Economics (1976) from Bethany College (West Virginia) and an MBA (1978) from Bowling Green State University in Ohio. He earned a Chartered Financial Analyst (CFA) in 1982.
John McDermott is Chief Executive Officer and a member of the Endologix Board of Directors. He joined Endologix in 2008 after spending 12 years at C.R. Bard (NYSE: BCR) in various leadership roles including President of Bard Peripheral Vascular, President of Global Sales for Vascular Surgery and Endovascular, and President of IMPRA, Inc. Prior to Bard he was the Chief Operating Officer of IMPRA, a private medical device company that was sold to Bard in 1996. Mr. McDermott joined IMPRA in 1990 as Chief Financial Officer after working for seven years in commercial banking. He is active in the medical device industry and currently serves on the Board of the Directors for the International Society of Endovascular Specialists. Mr. McDermott has three issued U.S. patents, a BS in Finance from Arizona State University, and an MBA from Western International University.
Mr. Christopher Chavez joined our board of directors February, 2016 following the completion of the merger between Endologix and TriVascular. Mr. Chavez joined TriVascular as President, Chief Executive Officer and Chairman in April 2012. Mr. Chavez has over 30 years of leadership experience in the medical device industry. From 2005 through August 2011, Mr. Chavez served as President of the Neuromodulation Division of St. Jude Medical, Inc., or St. Jude Medical, and served as CEO, President and Director of Advanced Neuromodulation Systems, or ANS, from 1998 until its acquisition by St. Jude Medical in 2005. Prior to ANS, Mr. Chavez spent 17 years at Johnson & Johnson, most recently as Vice President and General Manager of the Infection Control Business Unit. Mr. Chavez served on the board of directors of Advanced Medical Optics Inc. from 2002 until it was acquired by Abbott Laboratories Inc. in 2009. Mr. Chavez has previously served as Chairman of the Medical Device Manufacturers Association and Chairman of the Dallas/Fort Worth Health Industry Council. Mr. Chavez received his M.B.A. from Harvard Business School and his Bachelors of Accountancy from New Mexico State University, Las Cruces.
Mr. Guido Neels has served on our board of directors since December 2010. Mr. Neels is an Operating Partner at Essex Woodlands. Prior to joining Essex Woodlands in 2006, Mr. Neels served in a variety of management positions at Guidant Corporation, a developer of cardiovascular medical products. From July 2004 until retiring in November 2005, Mr. Neels served as Guidant's Chief Operating Officer, where he was responsible for the global operations of Guidant's four operating units: Cardiac Rhythm Management, Vascular Intervention, Cardiac Surgery, and Endovascular Solutions. From December 2002 to July 2004, Mr. Neels served as Guidant's Group Chairman, Office of the President, responsible for worldwide sales operations, corporate communications, corporate marketing, investor relations and government relations. In January 2000, Mr. Neels was named Guidant's President, Europe, Middle East, Africa and Canada. In addition, Mr. Neels served as Guidant's Vice President, Global Marketing, Vascular Intervention, from 1996 to 2000 and as Guidant's General Manager, Germany and Central Europe, from 1994 to 1996. Mr. Neels has a business engineering degree from the University of Leuven in Belgium and an M.B.A. from the Stanford University Graduate School of Business. Mr. Neels served on the boards of directors of Biopure Corporation, a publicly-traded medical device company, from 2005 to 2009, Lemaitre Vascular, Inc., a publicly-traded medical device company, from 2006 to 2008, and Nellix, Inc., a privately-held medical device company, from 2006 until its acquisition by us in December 2010. Mr. Neels currently serves on the boards of directors of AxoGen, Inc. and Entellus Medical, Inc., both publically held companies as well as 480 Biomedical, Inc., Arsenal Medical, Inc., and White Pine Medical, Inc., all privately-held medical device companies. He also serves on the board of Christel House International, a not-for-profit organization. Mr. Neels was appointed to our board of directors pursuant to a board designation right granted to Essex Woodlands Health Ventures Fund VII, L.P., or Essex Woodlands Fund VII, a stockholder of our company and an affiliate of Essex Woodlands, under a securities purchase agreement, dated as of October 27, 2010, as amended December 9, 2010, between us and Essex Woodlands Fund VII.
Ms. Leslie Norwalk has served on our board of directors since 2015. Ms. Norwalk currently serves as a Strategic Advisor and Strategic Counsel to the law firm Epstein Becker & Green, P.C., healthcare and life science consultancy EBG Advisors, Inc., and legislative and regulatory consultancy National Health Advisors. Ms. Norwalk is also an Operating Partner at Enhanced Equity Fund, L.P. and serves as an Advisor to Warburg Pincus LLC, and Peloton Equity. Previously, Ms. Norwalk served the Bush Administration as the Acting Administrator for the Centers for Medicare & Medicaid Services, where she managed the day-to-day operations of Medicare, Medicaid, State Child Health Insurance Programs, Survey and Certification of health care facilities and other federal health care initiatives. For four years prior to that, she was the agency’s Deputy Administrator, responsible for the implementation of the changes made under the Medicare Modernization Act, including the Medicare Prescription Drug Benefit. Prior to serving the Bush Administration, Ms. Norwalk practiced law in the Washington, D.C. office of Epstein Becker & Green, P.C. where she advised clients on a variety of health policy matters. She also served in the first Bush administration in the White House Office of Presidential Personnel, and the Office of the U.S. Trade Representative. Ms. Norwalk also serves as Member of International Advisory Council at APCO Worldwide Inc. She earned a J.D. degree from the George Mason University School of Law and a bachelor’s degree, cum laude, in Economics and International Relations from Wellesley College.
Gregory D. Waller has served on our board of directors since November 2003. Mr. Waller also serves on the board of Sunshine Heart Corporation, a publicly traded company, as Audit Committee Chairman and was the Chief Financial Officer of Ulthera Corporation, a privately held company that sells an ultrasound device used for non-invasive brow lifts from October of 2011 until its acquisition by Merz GMBH. He retired from Ulthera in April of 2015. From March 2006 until April 2011, Mr. Waller was Chief Financial Officer of Universal Building Products, a manufacturer of concrete construction accessories. Previous to that, Mr. Waller has been in retirement except for board directorships. Mr. Waller served as Vice President-Finance, Chief Financial Officer and Treasurer of Sybron Dental Specialties, Inc., a manufacturer and marketer of consumable dental products, from August 1993 until his retirement in May 2005 and was formerly the Vice President and Treasurer of Kerr, Ormco Corporation, and Metrex. Mr. Waller joined Ormco Corporation in December 1980 as Vice President and Controller and served as Vice President of Kerr European Operations from July 1989 to August 1993. Mr. Waller has an M.B.A. with a concentration in Accounting from California State University, Fullerton. Mr. Waller also served on the board of directors and audit committee of Cardiogenesis Corporation, a publicly-traded company until its acquisition by Cryolife in 2011. Mr. Waller also served on the boards of directors of Alsius Corporation, a publicly-traded company, from June 2007 to September 2009 until its acquisition by Zoll, Biolase Technology, Inc., a publicly-traded company, from October 2009 to August 2010, Clarient, Inc., a publicly-traded company which was acquired by General Electric Company on December 22, 2010, and SenoRx, Inc., a publicly-traded company which was acquired by C.R. Bard, Inc. on July 6, 2010.
Thomas Wilder has served on our board of directors since May 2010. He currently also serves on the board of Penumbra Inc. (PEN), a global interventional therapies company that designs, develops, manufactures and markets innovative medical devices, and on the board of Benvenue Medical Inc., a privately-held medical device company focused on the design, manufacture, and marketing of cutting edge products for the rapidly growing minimally invasive spinal surgery market. From February 2010, Mr. Wilder served as President and Chief Executive Officer of Sequent Medical, Inc., until it was acquired by Terumo Corporation in July 2016. From May 2009 to January 2010, Mr. Wilder consulted with several medical device companies. From April 2006 to April 2009, Mr. Wilder served as President and Chief Executive Officer of Photothera, Inc. From 2002 through January 2006, Mr. Wilder served at Micro Therapeutics, Inc. (MTIX) as President and Chief Executive Officer. Following the merger of Micro Therapeutics, Inc. into ev3 Inc. in January 2006, Mr. Wilder served as President, ev3 Neurovascular until April 2006. From 1991 to 2002, Mr. Wilder served in various roles for Medtronic, Inc. Mr. Wilder has a B.A. in Economics from Stanford University and an M.B.A. from Northwestern University's J.L. Kellogg Graduate School of Management.
Thomas F. Zenty, III has served on our board of directors since May 2013. He is currently the President and Chief Executive Officer of University Hospitals Health System, Inc., Cleveland, OH. Previously, Mr. Zenty held various executive positions at Cedars-Sinai Health System, St. Josephs Medical Center, a division of Catholic Health Care West, Franciscan Health System of New Jersey and St. Mary Hospital, Connecticut. Mr. Zenty is Chairman of the Board of Western Reserve Assurance Company, Ltd. SPC, a privately-held insurance company and chairs The Coalition to Protect American’s Health Care. Mr. Zenty is a past board member of the American Hospital Association and has also served on the board of directors of Nationwide Financial Services and Amerimed. Mr. Zenty has held several academic positions with prestigious universities, including his current position as Adjunct Professor, Banking & Finance at Case Western Reserve University. He received a Master’s degree in Public Administration from New York University, a Master’s degree in Hospital Administration from Xavier University, and a Bachelor’s degree in Health Planning from Pennsylvania State University.